1,003 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by PCM Encore LLC

PCM Encore LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,003 shares of the biopharmaceutical company’s stock, valued at approximately $625,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. BlackRock Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $5,682,636,000. Vanguard Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock valued at $7,004,838,000 after acquiring an additional 26,884 shares in the last quarter. Dodge & Cox grew its stake in shares of Regeneron Pharmaceuticals by 1.0% in the fourth quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock valued at $3,547,791,000 after acquiring an additional 45,513 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Regeneron Pharmaceuticals by 4.4% in the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock valued at $1,975,990,000 after acquiring an additional 106,861 shares in the last quarter. Finally, Nuveen LLC increased its position in Regeneron Pharmaceuticals by 71.1% during the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after acquiring an additional 835,240 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 1.7%

REGN stock opened at $826.64 on Friday. The company has a market cap of $85.11 billion, a PE ratio of 20.43, a price-to-earnings-growth ratio of 1.43 and a beta of 0.22. The business has a 50-day simple moving average of $692.65 and a 200 day simple moving average of $715.90. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $844.92. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. Regeneron Pharmaceuticals’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $12.81 earnings per share. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is 9.29%.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,400 shares of company stock valued at $1,090,030. Company insiders own 6.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on REGN. Cantor Fitzgerald lifted their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Wells Fargo & Company increased their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Truist Financial raised their target price on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Finally, TD Cowen lifted their price target on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a research report on Thursday, April 23rd. Sixteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $801.70.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder that causes abnormal bone formation. Approval was supported by Phase 3 OPTIMA data showing a 90% or greater reduction in new heterotopic-ossification lesions at 56 weeks, along with fewer clinician-assessed flare-ups. Pasatru is described as the first and only FDA-approved treatment demonstrating these benefits, adding a specialized rare-disease product to Regeneron’s commercial portfolio. Reuters FDA approval article
• Positive Sentiment: The approval creates a potential new revenue stream and strengthens Regeneron’s focus on high-complexity immunology and rare diseases. However, FOP’s very small patient population limits the drug’s absolute market opportunity, while competition from Ipsen could affect adoption and sales. BioPharma Dive Pasatru article
• Neutral Sentiment: Regeneron also reported an update to its Phase 2 study of olatorepatide, signaling continued efforts to enter the obesity-treatment market. The trial remains mid-stage, so any commercial benefit is still several steps away and dependent on future efficacy and safety results. TipRanks olatorepatide article
• Neutral Sentiment: Leerink Partners raised its price target to $824, indicating limited near-term upside relative to the trading level and suggesting the FDA approval may already be substantially reflected in the valuation. Leerink Partners price-target article
• Negative Sentiment: Multiple law firms publicized a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to disclosures surrounding the Phase 3 Fianlimab-Libtayo melanoma trial, including a protocol amendment and concerns that previously positive messaging did not adequately reflect statistical and trial risks. The notices are largely duplicative, but they reinforce legal, reputational and pipeline uncertainty for REGN. Regeneron securities class-action notice

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.